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Pharmacogenomics	 23	 66	 11	 17	 29	 56	
Germline	Sequencing	 23	 66	 11	 11	 72	 17	
Tumor	Sequencing	 17	 72	 11	 11	 60	 29	
Newborn	Sequencing	 64	 36	 0	 11	 72	 17	
Maternal-Fetal		Sequencing	 29	 65	 6	 11	 66	 23	
Rare	Disease	Diagnosis	 23	 71	 6	 6	 77	 17	
Microbial	Pathogen	Identification	 17	 72	 11	 11	 36	 53	
RNA	Profiling	 50	 50	 0	 11	 66	 23	
Metabolomics	 53	 47	 0	 11	 78	 11	
Proteomics	 64	 36	 0	 29	 60	 11	
Systematic	Family	History	 17	 36	 46	 6	 23	 71	
Genetic	Counselors	 23	 47	 30	 6	 17	 77	
Electronic	Medical	Record	 23	 47	 30	 6	 0	 94	
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Table	4.		Opportunities	for	international	collaborations.	
	
Evidence	generation	 	
• Catalog	ongoing	evidence-generating	projects		
• Assess	availability	of	data	and	specimens	
• Define	standards	for	evidence	
• Establish	standards	for	genetic	and	genomic	tests		
• Encourage	development	of	professional	practice	guidelines	
• Identify	countries/systems	willing	to	enable	access	to	patient	data	
• Develop	systems	to	capture	outcomes	from	EMRs	and	other	clinical	systems		
	
Health	information	technology	 	
• Define	key	elements	that	should	be	stored	in	EHR	
• Identify	and	share	existing	IT	solutions	that	are	more	robust	and	generalizable	(clinical	
decision	support,	variant	databases,	informatics	pipelines)	
• Develop	global	resource	for	actionable	clinical	variants	
• Define	and	link	necessary	federated	databases	needed	to	implement	genomic	medicine	
• Collect	and	aggregate	gene	and	variant	data	(e.g.	EVS,	ClinVar)	
• Develop	controlled	vocabulary	for	phenotypes	(ontology);	identify	available	ontologies	
• Establish	clearinghouse	of	genomic	medicine	implementation	guidelines	
	
Education/workforce	development	 	
• Genomics	professionals	
o Collect	data	on	genomic	professional	workforce	and	training	in	different	
countries	
o Summarize	existing	workforce	surveys	and	conduct	new	ones	as	needed		
o Share	competencies	and	training	paradigms	
o Compare	training	paradigms	for	geneticists	and	identify	best	practices		
o Examine	extending	current	capabilities	by	telemedicine	and	other	remote	
approaches	
• Other	health	professionals	
o Examine	curricula	and	determine	where	genetics	competency	training	can	be	
accommodated	
o Define	necessary	genomic	competencies	for	trainees	at	completion	of	training,	
which	may	differ	across	regions/countries	
o Deploy	new	educational	tools,	such	as	distance	learning		
o Develop	region/country-specific	teaching	materials,	perhaps	on	common	
templates	
• Public	
o Adapt	existing	products	and	activities	such	as	DNA	Day	to	specific	cultures		
o Extend	to	students	at	secondary	school	level	
o Engage	patient	support	groups	to	sponsor	programs,	develop	and	distribute	
educational	materials	
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o Provide	clearinghouse	for	accumulated	educational	resources		
o Consider	novel	educational	paradigms	
	
Pharmacogenomics	 	
• Promote	improved	quality	of	evidence	base	for	pharmacogenomics	implementation	
• Prioritize	for	study	and	implementation	inexpensive	drugs	with	risk	of	treatment	failure	
or	severe	adverse	drug	reactions	likely	to	be	limited	to	genetically	defined	subset	
• Develop	and	pilot	large-scale	implementation	project	around	successful	programs	such	
as	global	eradication	of	genetically-mediated	SJS/TEN		
	
Policy	
• Data	sharing	and	regulatory	issues	
o Map	current	activities	and	issues	being	addressed	
o Perform	gap	analysis	
o Establish	“network	of	networks”	in	policy	development	to	share	information	
• Costs	and	benefits	
o Identify	burdens	of	disease	and	points	in	care	pathway	where	genomic	tools	
would	integrate	and	have	the	greatest	impact	on	outcomes	
o Improve	capacity	for	conducting	convincing	economic,	feasibility,	and	
sustainability	analyses		
o Perform	economic,	feasibility,	and	sustainability	analyses	from	perspective	of	
different	stakeholders	such	as	payers,	delivery	systems,	national	health	services		
o Engage	payers	and	payment	decision	processes	
o Work	in	and	learn	from	systems	with	one	or	a	few	centralized	payers	
	
	 	
